6 stories mentioning SHA:688185Updated 31d ago
Every FINWIRES story that references SHA:688185, newest first.
CanSino Biologics (SHA:688185, HKG:6185) obtained approval for its new drug application for the adsorbed tetanus vaccine from China's National Medical Products Administration, according to a Thursday bourse filing.
CanSino Biologics (SHA:688185, HKG:6185) obtained acceptance from China's medical products administrator for its drug registration and marketing authorization application for its adsorbed acellular pertussis, diphtheria and tetanus combined vaccine.The vaccine is intended for persons aged six years and above, according to a Monday filing with the Shanghai bourse.Shares of the vaccine manufacturer closed 3% higher Monday.
CanSino Biologics' (HKG:6185, SHA:688185) new drug application for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine was accepted by China's National Medical Products Administration, according to an Aug. 16 Hong Kong bourse filing.Shares of the vaccine maker were up 2% in Monday afternoon trading.The product is a booster vaccine for diphtheria, tetanus, and acellular pertussis for adolescents and adults aged six years and above.
CanSino Biologics' (HKG:6185, SHA:688185) ACYW135 Meningococcal Polysaccharide Conjugate Vaccine received a drug registration certificate from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.The product is used for the prevention of epidemic cerebrospinal meningitis associated with ACYW135 Neisseria meningitidis, according to a Thursday Hong Kong bourse filing.
CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
